The introduction of noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) affects the risk of malignancy (ROM) mostly in the Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) categories. In this multi-institutional, retrospective study, the authors investigated variations in the impact of an NIFTP diagnosis on the associated ROM for each TBSRTC category with an emphasis on the influence of pathologist and institutional diagnostic thresholds on the ROM. METHODS: Baseline data on cytology and histology diagnostic categories were collected over a 3-year period at 3 academic center hospitals (institutions A, B, and C). Histology slides for all cases diagnosed as follicular variant of papillary thyroid carcinoma (FVPTC) were re-reviewed at each institution, and those that qualifying as NIFTP were separated from other PTCs. RESULTS: The collective case cohort from the 3 institutions included 15,973 thyroid fine-needle aspiration cytology (FNAC) specimens and 5090 thyroid surgical resection specimens. Significant differences in baseline cytology and histology data were noted among the 3 institutions. The number of cases classified as NIFTP compared with FVPTC was highly variable (institution A, 14%; institution B, 39%; and institution C, 12%). For 3250 resected thyroid nodules with a previous FNAC diagnosis, the average decrease in ROM after the exclusion of NIFTP for all TBSRTC categories was as follows: institution A, 9.8%; institution B, 3.9%; and institution C, 1.3%. CONCLUSIONS:
INTRODUCTION
Thyroid fine-needle aspiration cytology (FNAC) is an essential step for the evaluation and management of thyroid nodules. 1, 2 Currently, most thyroid FNAC specimens are classified based on various tiered classification schemes, and the most is the Bethesda System for Reporting Thyroid Cytopathology (TBSRTC). This system includes 6 diagnostic categories 1, [3] [4] [5] [6] which are associated with a suggested risk of malignancy (ROM) and are used along with the clinical and radiologic impression for the subsequent management of patients with thyroid nodules. 1 The most common malignant tumor encountered in the thyroid is papillary thyroid carcinoma (PTC). It has been well documented in the literature that the incidence of PTC has nearly tripled over the past few decade, largely because of "incidentalomas" detected by the widespread use of imaging studies. The majority of these are small (ie, measuring < 1 cm), encapsulated, and of no biologic significance. There has also been an exponential, yet poorly reproducible rise in the histopathologic diagnosis of encapsulated/noninvasive follicular variant of PTC (NI-FVPTC). However, unlike classic PTC or its other variants, the biologic behavior of NI-FVPTC is similar to that of follicular adenoma, 7, 8 with virtually nonexistent metastases and recurrences. [9] [10] [11] The reclassification of NI-FVPTC into a low-risk neoplasm by a panel of endocrine experts has been a recent hot topic in the medical literature and lay press. [12] [13] [14] [15] The new diagnostic term for NI-FVPTC, noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP), is meant to convey the better prognosis of this variant and avoid overtreatment (ie, near-total thyroidectomy and radioactive iodine treatment). 16 Retrospective analyses have demonstrated that introduction of the NIFTP nomenclature has affected the ROM for each of the TBSRTC diagnostic categories. Various institutions have demonstrated that, if NIFTP were no longer termed carcinoma, then there would be an appreciable decrease in the ROM for the TBSRTC diagnostic categories atypia of undetermined significance/follicular lesion of undetermined significance (AUS/FLUS), follicular neoplasm/suspicious for follicular neoplasm (FN/SFN), and suspicious for malignancy (SM). 17, 18 This has raised well founded concerns among cytopathologists regarding how to classify follicular-patterned lesions that have the focal features of PTC on cytology and how this change in approach will affect downstream patient management.
In the current study, we add our multi-institutional, retrospective experience to the existing literature on the impact of reclassifying NIFTPs on the ROM for each diagnostic Bethesda category. In addition, we also present how this change in ROM depends both on the pathologist and on the institutional diagnostic trends in the use of TBSRTC cytology categories and subsequent histopathologic diagnosis.
MATERIALS AND METHODS
The case cohort comprised FNAC cases and thyroid resection cases collected from 3 academic institutions: the Hospital of the University of Pennsylvania (Philadelphia, PA), Catholic University Hospital (Rome, Italy), and Northwestern University/Northwestern Memorial Hospital (Chicago, IL; institution A, B, and C, respectively). Institutional review board approval was obtained at all the institutions.
At all 3 institutions, most thyroid nodules were evaluated and biopsied under ultrasound guidance by clinicians and radiologists. All FNAC specimens from Catholic University were processed using a liquid-based cytology method with ThinPrep 5000 processing (Hologic, Marlborough, MA) and alcohol-fixed Papanicolaou stain; whereas, at the other 2 institutions, specimens were processed as both air-dried Diff-Quick-stained and alcoholfixed Papanicolaou-stained smears.
Thyroid FNAC cases from January 1, 2013, to December 30, 2015, were identified through a retrospective laboratory database search at each institution and were classified according to TBSRTC as nondiagnostic (ND), benign, AUS/FLUS, FN/SFN, SM, or malignant (M). The thyroid resection cases for the same period were also collected and classified according to World Health Organization diagnostic categories as adenomatoid nodule, follicular adenoma, follicular carcinoma, PTC and its variants, or other benign and malignant lesions.
Cytologic-histologic correlation was performed by matching the FNAC-sampled nodule with the corresponding surgical follow-up diagnosis. Cases of incidental papillary thyroid microcarcinoma within the surgical resection specimen that were not the target of the FNAC were excluded from our analyses.
All surgical pathology reports with a diagnosis of FVPTC were analyzed. All cases that fit the description of NI-FVPTC were reviewed by 1 or more of the authors. NIFTP cases were identified from within the NI-FVPTC cohort(s) based on the sampling of the tumor (complete submission of the tumor nodule) and diagnostic inclusion and exclusion criteria. 16 The ROM for each TBSRTC diagnostic category was calculated by dividing the total number of malignant cases by the number of cases that had surgical follow-up.
RESULTS

Institutional TBSRTC Rates and Thyroid Surgical Resection Pathology
All 3 institutions included in this study have a large volume of thyroid cytology specimens (see Table 1 ). In total, 15,973 thyroid FNAC cases were retrieved from the 3 institutions. The overall TBSRTC diagnostic category rates, irrespective of follow-up surgical resection at institutions A, B, and C were as follows: ND rate, 4%, 5%, and 6%, respectively; benign rate, 66%, 79%, and 75%, respectively; AUS/FLUS rate, 13%, 5%, and 9%, respectively; FN/SFN rate, 10%, 5%, and 3%, respectively; SM rate, 2%, 2%, and 1%, respectively; and M rate, 5%, 4%, and 6%, respectively. The trends in the cytology reporting rate for nodules at each individual institution were quite comparable in 4 TBSRTC categories; however, the rates for AUS/FLUS and FN/SFN were significantly higher at institution A. The 3-year thyroid resection pathology data from all 3 institutions, irrespective of prior cytology, were collected ( Table 2 ). In total, 5090 thyroid surgical resection cases were retrieved, and the diagnostic rate for PTC in surgical pathology specimens for institution A, B, and C was 65%, 22%, and 41%, respectively. Of these, FVPTC as a percentage of all PTC cases by report review was 34%, 46%, and 23% for institution A, B and C, respectively; and, on retrospective review of reports and slides, NIFTP as a percentage of all FVPTC was 14%, 39% and 12%, respectively. It is noteworthy that institution B had a significantly lower rate of malignancy yield and PTC but much higher rates of FVPTC, NIFTP, and follicular adenoma diagnoses.
NIFTP and ROM Decrease
In total, 3250 resected thyroid nodules had a previous, matched FNAC diagnosis from the 3 institutions (Table  3) . Upon reclassifying the cases of NI-FVPTC as NIFTP, the impact on ROM varied widely among all 3 institutions. The greatest decrease in ROM was noted in the indeterminate categories AUS/FLUS, FN/SFN, and SM. The ROM decrease ranged from 5.2% to 15% for AUS/ FLUS, from 3.9% to 11.2% for FN/SFN, and from 0% to 26.8% for SM. At all 3 institutions, there was no change in the ROM (0%) for the ND category; the ROM decrease was minimal (range, 0%-2.5%) for the benign Original Article
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Cancer Cytopathology category; and the ROM decrease was low (range, 0.4%-4/ 4%) for the M category. The total rate of ROM decrease varied from 9.8 % at institution A, to 3.9% at institution B, to 1.3% at institution C.
NIFTP and ROM Decrease in the Current Study and Literature Reports
The aggregate data from this study were compared with previously published reports and professional society meeting abstracts (Table 4) 17-24 for thyroid nodules that had a previous matched FNAC diagnosis. With the introduction of NIFTP, decreases in the ROM for cytology diagnostic categories were quite variable among different institutions.
For the Bethesda categories, the ROM decrease varied as follows: benign, 0% to 7.8%; AUS/FLUS, 3.3% to 17.6%; FN/SFN, 2% to 36%; SM, 0% to 41.5%; and M, 0% to 12.8%. We also compared the previous matched FNAC diagnosis for the histopathology diagnosis of NIFTP, both in our current study and in previously published reports (Table 5) . 17, 18, 23, [25] [26] [27] [28] 
DISCUSSION
Introduction of the new NIFTP nomenclature will have significant consequences for the management of patients with thyroid nodules. This diagnosis in itself describes a lowgrade/low-risk neoplasm with a less than 1% chance of recurrence, as anticipated, and thus will prevent overtreatment (ie, near total thyroidectomy and radioactive iodine ablation). 16 Several published studies have demonstrated that the exclusion of NIFTP from the M category will impact the preoperative cytologic diagnosis classified according to TBSRTC. 17, 18, 29, 30 The most notable effect will be observed as a "decrease in ROM" in the indeterminate diagnostic categories of AUS/FLUS, FN/SFN, and SM. In a study of 6943 patients from 5 academic institutions, Faquin et al demonstrated that the impact of NIFTP reclassification on the ROM was mostly relevant for the indeterminate categories, including decreases ranging from 5.2% to 13.6% for AUS/FLUS; from 9.9% to 15.1% for FN/ SFN; and from 17.6% to 23.4% for SM. 17 Howitt and coworkers analyzed a series of 72 NIFTPs and observed the most significant decrease in the ROM (48.6%) in the SM category. 29 Similar findings have been reported by Ustun et al 30 In the current multi-institutional study, we also observed that the reclassification of NI-FVPTC as NIFTP decreased the ROM for the indeterminate categories (8.7% for AUS/ FLUS, 7.9% for FN/SFN and 10.9% for SM); however, the impact overall, and especially on the SM category, was significantly lower that than in many published studies.
It is important to note that, in the current study, we attribute the variable decrease in ROM to the considerable variability in pathologists' cytologic and histopathologic diagnostic thresholds and in clinicians' thresholds for surgical management. This is striking even, in institutions such as ours with a significant case load and experience in thyroid pathology (Table 4) . [17] [18] [19] [20] [21] [22] [23] [24] According to the literature, the majority of NIFTPs belong to the indeterminate categories, and they were and are handled with suggestions for the specific diagnostic categories in TBSRTC. Indeed, as demonstrated by our results, the ROM variability is directly related to the rates of AUS/FLUS, FN/SFN, and SM on FNA cytology and the frequency of diagnosis of FVPTC and NI-FVPTC (now NIFTP) and follicular adenoma in the follow-up surgical pathology specimens. In addition, the rates of ROM may also differ among institutions because of patient-specific demographics/history, radiologic features of biopsied nodules (low vs high suspicion), and thresholds for clinicians' surgical management.
In the current study, we did not analyze these factors.
The FVPTC rate as a percentage of all PTCs at institutions A, B, and C was 34%, 46%, and 23%, respectively; and the follicular adenoma rate was 18%, 43%, and 25%, respectively. After a review of slides and reclassification of FVPTC, the NIFTP rate as a percentage of all FVPTCs was 14%, 39%, and 12%, respectively.
The reporting rate of NIFTP on histopathology is quite variable in the published data, 17, 18, 23, [25] [26] [27] [28] which may be caused by multiple factors, including patient demographics, referral patterns, and the diagnostic threshold of individual cytopathologists and surgical pathologists. Currently, FVPTC represents a significant proportion (approximately 15%-20%) of PTC diagnoses with increasing incidence. 7, 12, 13, 18, 31, 32 With the nomenclature change from NI-FVPTC to NIFTP, a significant fraction of these PTCs will be excluded from classification as malignant. 16 This will place a significant challenge on preoperative cytology diagnosis, because NIFTP is ultimately a histopathology interpretation, and its diagnosis is to be made after the application of strict inclusion and (more important) exclusion criteria. Although cytology features like high cellularity, greater nuclear enlargement, fewer grooves, etc, favor IFVPTC versus NIFTP, distinct reproducible cytologic diagnostic criteria are not available to differentiate NIFTP from IFVPTC on cytology. 26, 27, [33] [34] [35] Therefore, it is critical that pathologists review their personal and institutional thresholds for TBSRTC diagnostic categories and closely monitor cytology quality-assurance measures, specifically cytologic-histologic correlation, to avoid the stigma of increasing false-positive diagnoses. Similarly, those practicing surgical pathology of the thyroid should review their grossing technique for encapsulated thyroid tumors and their relative thresholds for diagnosing follicular adenoma versus FVPTC.
In conclusion, the current study confirms the findings reported by others and highlights the inherent interinstitutional differences in cytology and histology reporting of thyroid lesions and their potential corresponding effect on the suggested ROM associated with TBSRTC diagnostic categories. A range in decreased ROM among the TBRSTC categories is valid with the new terminology of NIFTP, but caution is warranted in making assumptions about the rate of decrease without considering the baseline cytology and histology reporting characteristics of an individual practice setting. In addition, it should be remembered that a follow-up finding of NIFTP after a cytology diagnosis does not equate to a completely benign lesion. It is a low-risk neoplasm, which portends an indolent clinical course with <1% chance of recurrence. Thus it may be important for future studies to consider a 3-pronged approach for cytologic-histologic correlation (benign, neoplasm, and malignant) rather than the traditional binary approach of benign or malignant.
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